TESARO, Inc. (TSRO) Rating Reiterated by Citigroup Inc.
TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “buy” rating reissued by research analysts at Citigroup Inc. in a research note issued on Monday. They presently have a $216.00 price objective on the biopharmaceutical company’s stock. Citigroup Inc.’s target price points to a potential upside of 82.71% from the stock’s current price.
A number of other equities research analysts have also recently weighed in on TSRO. Cann restated an “outperform” rating on shares of TESARO in a report on Wednesday, May 24th. Oppenheimer Holdings, Inc. initiated coverage on shares of TESARO in a research note on Thursday, May 25th. They issued an “outperform” rating and a $183.00 target price on the stock. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. FBR & Co dropped their target price on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research note on Monday, June 5th. Finally, Wedbush upgraded shares of TESARO to an “outperform” rating and set a $168.00 target price on the stock in a research note on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. TESARO currently has a consensus rating of “Buy” and an average price target of $175.15.
TESARO (NASDAQ:TSRO) opened at 118.22 on Monday. TESARO has a 12 month low of $91.76 and a 12 month high of $192.94. The company has a 50-day moving average of $123.15 and a 200 day moving average of $141.79. The company’s market cap is $6.41 billion.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). The business had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. TESARO’s revenue for the quarter was down 17.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.28) EPS. On average, equities analysts forecast that TESARO will post ($8.67) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/13/tesaro-inc-tsro-rating-reiterated-by-citigroup-inc.html.
In other news, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at $844,329.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,100 shares of company stock valued at $3,387,465. Corporate insiders own 34.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vident Investment Advisory LLC purchased a new position in TESARO during the first quarter valued at $351,000. Botty Investors LLC purchased a new position in TESARO during the second quarter valued at $140,000. Meeder Asset Management Inc. purchased a new position in TESARO during the first quarter valued at $177,000. Nordea Investment Management AB purchased a new position in TESARO during the second quarter valued at $167,000. Finally, Oppenheimer Asset Management Inc. grew its stake in TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 1,430 shares in the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.